VelaVigo Announces Exclusive Option Agreement with Avenzo to License a Potential First-in-Class Nectin4/TROP2 Bispecific Antibody-Drug Conjugate

CAR-T Digest - August 2020

Weekly Digest - November 2024

18 Nov 2024: VelaVigo Announces Exclusive Option Agreement with Avenzo to License a Potential First-in-Class Nectin4/TROP2 Bispecific Antibody-Drug Conjugate

VelaVigo Cayman Limited has entered into an agreement with Avenzo Therapeutics, granting Avenzo an exclusive option to license and develop a first-in-class Nectin4/TROP2 bispecific antibody-drug conjugate (ADC) globally, excluding Greater China
VelaVigo will retain rights for the Greater China region and plans to collaborate with Avenzo for global development of the bispecific ADC
VelaVigo’s pipeline includes over ten first-in-class (FIC) and best-in-class (BIC) multi-specific antibodies and ADCs for oncology and autoimmune diseases, with plans for clinical development in the US
The agreement includes an upfront fee and potential near-term milestones of up to $50 million, along with up to $750 million in future development, regulatory, and commercial milestone payments
VelaVigo is also eligible for tiered royalties on sales in Avenzo’s territory as part of the partnership agreement
The companies plan to submit an Investigational New Drug (IND) application for the Nectin4/TROP2 ADC to the FDA and Chinese NMPA in 2025